Radiologist detection of microcalcifications with and without computer-aided detection: A comparative study

Aim: To compare the sensitivity and specificity of microcalcification detection by radiologists alone and assisted by a computer-aided detection (CAD) system. Materials and Methods: Films of 106 patients were masked, randomized, digitized and analysed by the CAD-system. Five readers interpreted the original mammograms and were blinded to demographics, medical history and earlier films. Forty-two mammograms with malignant microcalcifications, 40 with benign microcalcifications; and 24 normal mammograms were included. Results were recorded on a standardized image interpretation form. The mammograms with suspicious areas flagged by the CAD-system were displayed on mini-monitors and immediately re-reviewed. The interpretation was again recorded on a new copy of the standard form and classified according to six groups. Results: Forty-one out of 42 (98%) malignant microcalcifications and 32 of 40 (80%) benign microcalcifications were flagged by the CAD-system. There was an average of 1.2 markers per image. The sensitivity for malignant microcalcifications detection by mammographers without and with the CAD-system ranged from 81% to 98% and from 88% to 98%, respectively. The mean difference without and with CAD-system was 2.2% (range 0-7%). Conclusion: No statistically significant changes in sensitivity were found when experienced mammographers were assisted by the CAD-system, with no significant compromise in specificity. © 2001 The Royal College of Radiologists

Accuracy of mammographic and sonographic assessment of preoperative breast cancer size

Evaluation of breast cancer size is important for preoperative surgical planning and determining response to neoadjuvant chemotherapy. Due to the limitations of clinical breast examination, imaging assessment of tumor size is important. The purpose of this study is to compare preoperative breast cancer size as determined by mammography and sonography and correlate to pathologic size. In 117 invasive breast cancers, tumor size was measured mammographically and sonographically prior to surgery and correlated with postexcisional pathologic measurement by regression linear analysis. The tumor histologic type was considered in the correlations. Mammographic (r = 0.8585) and sonographic (r = 0.8701) measurements of tumor size correlated well with pathologic size. The correlation persisted when evaluating the differing histopathologic types of breast cancer and was greater for infiltrating lobular carcinoma than infiltrating ductal carcinoma. Both mammography and sonography can accurately measure tumor size preoperatively, regardless of breast cancer histopathology

High-resolution scintimammography: A pilot study

This study evaluated a novel high-resolution breast-specific gamma camera (HRBGC) for the detection of suggestive breast lesions. Methods: Fifty patients (with 58 breast lesions) for whom a scintimammogram was clinically indicated were prospectively evaluated with a general-purpose gamma camera and a novel HRBGC prototype. The results of conventional and high-resolution nuclear studies were prospectively classified as negative (normal or benign) or positive (suggestive or malignant) by 2 radiologists who were unaware of the mammographic and histologic results. All of the included lesions were confirmed by pathology. Results: There were 30 benign and 28 malignant lesions. The sensitivity for detection of breast cancer was 64.3% (18/28) with the conventional camera and 78.6% (22/28) with the HRBGC. The specificity with both systems was 93.3% (28/30). For the 18 nonpalpable lesions, sensitivity was 55.5% (10/18) and 72.2% (13/18) with the general-purpose camera and the HRBGC, respectively. For lesions ≤ 1 cm, 7 of 15 were detected with the general-purpose camera and 10 of 15 with the HRBGC. Four lesions (median size, 8.5 mm) were detected only with the HRBGC and were missed by the conventional camera. Conclusion: Evaluation of indeterminate breast lesions with an HRBGC results in improved sensitivity for the detection of cancer, with greater improvement shown for nonpalpable and ≤1-cm lesions

Nonpalpable breast cancer: Percutaneous diagnosis with 11- and 8-gauge stereotactic vacuum-assisted biopsy devices

PURPOSE: To compare the accuracy of diagnosis of invasive breast cancer with 11- and 8-gauge stereotactic vacuum-assisted biopsy (SVAB) devices and to correlate lesion diameter and accuracy of breast cancer diagnosis at SVAB. MATERIALS AND METHODS; During a 22-month period, 489 SVAB procedures were performed with an 11-gauge probe and 305 with an 8-gauge probe. SVAB and surgical pathologic results of 104 breast carcinomas were reviewed and correlated with lesion size, number of specimens obtained, and type of SVAB probe used. RESULTS: Four of 38 ductal carcinoma in situ (DCIS) lesions diagnosed with 11-gauge SVAB demonstrated invasion at surgery, whereas one of 23 DCIS lesions diagnosed with 8-gauge SVAB demonstrated invasion at surgery (P = .6). A mean of 12 specimens per lesion were obtained in each group. In lesions 30 mm or larger, the underestimation rate for DCIS was 43% (three of seven) with 11-gauge SVAB and 17% (one of six) with 8-gauge SVAB (P = .6). Overall, the rate of underestimation for DCIS was significantly higher in lesions 30 mm or larger (four of 13) than in smaller lesions (one of 48, P = .006). CONCLUSION: This study demonstrated no difference in breast cancer diagnosis with the 8- and 11 -gauge SVAB systems, but the accuracy of breast cancer diagnosis was greater in lesions smaller than 30 mm than in larger lesions

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.

LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%). BACKGROUND: Cabazitaxel is a second-generation taxane that improves the survival of patients with metastatic castrate-resistant prostate cancer following docetaxel therapy. Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. In this randomized phase II trial, we investigated cabazitaxel in patients with recurrent SCCHN. METHODS: Patients with incurable SCCHN with progression after platinum-based therapy were randomly assigned to cabazitaxel every 3 weeks (cycle 1, 20 mg/m2, increased to 25 mg/m2 for subsequent cycles in the absence of nonhematological adverse events [AEs] greater than grade 2 and hematological AEs greater than grade 3) or methotrexate (40 mg/m2/week). The patients were stratified according to their performance status and previous platinum-based chemotherapy for palliation versus curative intent. The primary endpoint was the progression-free survival rate (PFSR) at 18 weeks. RESULTS: Of the 101 patients, 53 and 48, with a median age of 58.0 years (range, 41-80), were randomly assigned to cabazitaxel or methotrexate, respectively. The PFSR at 18 weeks was 13.2% (95% confidence interval [CI], 5%-25%) for cabazitaxel and 8.3% (95% CI, 2%-20%) for methotrexate. The median progression-free survival was 1.9 months in both arms. The median overall survival was 5.0 and 3.6 months for cabazitaxel and methotrexate, respectively. More patients experienced serious adverse events with cabazitaxel than with methotrexate (54% vs. 36%). The most common drug-related grade 3-4 AE in the cabazitaxel arm was febrile neutropenia (17.3%). CONCLUSION: This study did not meet its primary endpoint. Cabazitaxel has low activity in recurrent SCCHN